The anti-Covid 19 vaccine is a huge success for the laboratories that market it.
A week after Pfizer, Moderna once again increased the revenue generated by its messenger RNA serum, the second authorized for vaccination against Covid-19.
Read also:
Moderna's vaccine is now available to adolescents
The American biotech, which had never commercialized a treatment until now, plans to achieve 20 billion dollars in sales this year, against 19.2 billion dollars announced in May.
The group will sell between 800 million and 1 billion doses this year.
"We have reached our maximum capacity and we do not take more orders for 2021"
, says the
BBC
Stéphane Bancel, CEO of Moderna.
Develop production capacities
Biotech has already signed contracts worth $ 12 billion for 2022, to which could be added $ 8 billion in call options.
"We are in discussions with many countries," said
the Marseille leader.
Moderna plans to manufacture between 2 billion
This article is for subscribers only.
You have 77% left to discover.
To cultivate your freedom is to cultivate your curiosity.
Continue reading your article for € 1 for 2 months
I ENJOY IT
Already subscribed?
Log in
